Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation

Cen, Chao; Fang, Haixing; Yu, Songfeng; Liu, Jimin; Liu, Yuan; Zhou, Lin; Yu, Jun; Zheng, Shusen

doi:10.1016/s1499-3872(17)60069-9

Cited by 10 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study investigated the association of genetics with PTDM in a white UK renal transplant population; 26 SNPs were associated with PTDM, such as ATP5F1P6 rs1048482, DNAJC16 rs7533125, and CELA2B rs2861484 [46]. Other associations of specific gene variants with PTDM include KCNQ1 SNP rs2237895 [47], NFATc4 [48], HNF1B [49], adiponectin rs1501299 [50], mitochondrial haplotype H [51], CDKAL1 rs10946398 [51], KCNJ11 rs5219 and rs5215 SNPs [52], and NPPA rs198372 [53]. While these associations are interesting, the findings have not been independently replicated in different populations.…”

Section: Transplant Genetics Epigenetics and Their Association With Ptdmmentioning

confidence: 99%

Genetic and Epigenetic Associations with Post-Transplant Diabetes Mellitus

Abdelrahman,

Maxwell,

McKnight

2024

Genes

View full text Add to dashboard Cite

Post-transplant diabetes mellitus (PTDM) is a common complication of solid organ transplantation. PTDM prevalence varies due to different diabetes definitions. Consensus guidelines for the diagnosis of PTDM have been published based on random blood glucose levels, glycated hemoglobin (HbA1c), and oral glucose tolerance test (OGTT). The task of diagnosing PTDM continues to pose challenges, given the potential for diabetes to manifest at different time points after transplantation, thus demanding constant clinical vigilance and repeated testing. Interpreting HbA1c levels can be challenging after renal transplantation. Pre-transplant risk factors for PTDM include obesity, sedentary lifestyle, family history of diabetes, ethnicity (e.g., African-Caribbean or South Asian ancestry), and genetic risk factors. Risk factors for PTDM include immunosuppressive drugs, weight gain, hepatitis C, and cytomegalovirus infection. There is also emerging evidence that genetic and epigenetic variation in the organ transplant recipient may influence the risk of developing PTDM. This review outlines many known risk factors for PTDM and details some of the pathways, genetic variants, and epigenetic features associated with PTDM. Improved understanding of established and emerging risk factors may help identify people at risk of developing PTDM and may reduce the risk of developing PTDM or improve the management of this complication of organ transplantation.

show abstract

Section: Transplant Genetics Epigenetics and Their Association With Ptdmmentioning

confidence: 99%

Genetic and Epigenetic Associations with Post-Transplant Diabetes Mellitus

Abdelrahman,

Maxwell,

McKnight

2024

Genes

View full text Add to dashboard Cite

show abstract

“…Common polymorphisms in recipient genes involved in metabolic homeostasis and inflammatory response-SUMO4, ADIPOQ, Angiotensinogen, STAT4, IL-18, mTOR-have been associated with an increased risk of PTDM, but evidence arises mostly from small Asian studies and needs further validation. [188][189][190][191][192]…”

Section: Genesmentioning

confidence: 99%

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients

et al. 2021

View full text Add to dashboard Cite

Diabetes is common in patients waitlisted for liver transplantation because of end-stage liver disease or hepatocellular cancer as well as in posttransplant phase (posttransplantation diabetes mellitus). In both conditions, the presence of diabetes severely affects disease burden and long-term clinical outcomes; careful monitoring and appropriate treatment are pivotal to reduce cardiovascular events and graft and recipients' death. We thoroughly reviewed the epidemiology of diabetes in the transplant setting and the different therapeutic options, from lifestyle intervention to antidiabetic drug use-including the most recent drug classes available-and to the inclusion of bariatric surgery in the treatment cascade. In waitlisted patients, the old paradigm that insulin should be the treatment of choice in the presence of severe liver dysfunction is no longer valid; novel antidiabetic agents may provide adequate glucose control without the risk of hypoglycemia, also offering cardiovascular protection. The same evidence applies to the posttransplant phase, where oral or injectable noninsulin agents should be considered to treat patients to target, limiting the impact of disease on daily living, without interaction with immunosuppressive regimens. The increasing prevalence of liver disease of metabolic origin (nonalcoholic fatty liver) among liver transplant candidates, also having a higher risk of noncirrhotic hepatocellular cancer, is likely to accelerate the acceptance of new drugs and invasive procedures, as suggested by international guidelines. Intensive lifestyle intervention programs remain however mandatory, both before and after transplantation. Achievement of adequate control is mandatory to increase candidacy, to prevent delisting, and to improve long-term outcomes.

show abstract

“…For diabetic liver transplant recipients, the treatment should be based on diet therapy, lifestyle modification, including exercise and weight loss (for obese recipients), and further adjustment of the immunosuppressive regimen and appropriate use of hypoglycemic drugs. Some studies have shown that the risk of NODAT increases by 5%[ 31 ] with a prednisone dose increase of 0.01 mg/kg. Compared with conventional glucocorticoid-based regimens, glucocorticoid-free or early withdrawal regimens can significantly reduce PTDM[ 32 , 33 ], while the use of basiliximab and MPA makes the glucocorticoid-free or early withdrawal regimen safe and feasible.…”

Section: Recommendations For the Prophylaxis And Treatment Of Metabolmentioning

confidence: 99%

Expert consensus on management of metabolic disease in Chinese liver transplant recipients

Shen

Li²,

Sun

et al. 2020

WJG

Self Cite

View full text Add to dashboard Cite

Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosuppressants. Therefore, optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic disease. The Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent studies. Emphasis is placed on the risk factors of metabolic diseases, the effect of immunosuppressants on metabolic disease, and the prevention and treatment of metabolic diseases.

show abstract

Association between ADIPOQ gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation

Cited by 10 publications

References 37 publications

Genetic and Epigenetic Associations with Post-Transplant Diabetes Mellitus

Genetic and Epigenetic Associations with Post-Transplant Diabetes Mellitus

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients

Expert consensus on management of metabolic disease in Chinese liver transplant recipients

Contact Info

Product

Resources

About